HCA Healthcare, Inc. (NYSE:HCA) Shares Sold by Narwhal Capital Management

Narwhal Capital Management lessened its position in shares of HCA Healthcare, Inc. (NYSE:HCA) by 14.9% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 23,220 shares of the company’s stock after selling 4,058 shares during the period. Narwhal Capital Management’s holdings in HCA Healthcare were worth $9,437,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. MFA Wealth Advisors LLC purchased a new position in shares of HCA Healthcare in the 2nd quarter valued at about $27,000. Unique Wealth Strategies LLC acquired a new stake in HCA Healthcare during the 2nd quarter worth $28,000. Bangor Savings Bank grew its holdings in shares of HCA Healthcare by 112.5% during the second quarter. Bangor Savings Bank now owns 85 shares of the company’s stock worth $27,000 after purchasing an additional 45 shares during the last quarter. GPS Wealth Strategies Group LLC boosted its position in shares of HCA Healthcare by 284.0% in the 2nd quarter. GPS Wealth Strategies Group LLC now owns 96 shares of the company’s stock valued at $31,000 after purchasing an additional 71 shares during the period. Finally, Benjamin F. Edwards & Company Inc. acquired a new position in HCA Healthcare during the second quarter worth approximately $33,000. 62.73% of the stock is owned by hedge funds and other institutional investors.

HCA Healthcare Price Performance

HCA opened at $408.17 on Wednesday. The company has a debt-to-equity ratio of 27.11, a quick ratio of 0.94 and a current ratio of 1.06. The stock has a market capitalization of $106.91 billion, a PE ratio of 20.35, a P/E/G ratio of 1.44 and a beta of 1.67. HCA Healthcare, Inc. has a 1 year low of $215.96 and a 1 year high of $417.14. The company’s 50 day simple moving average is $393.95 and its 200 day simple moving average is $351.69.

HCA Healthcare (NYSE:HCA) last posted its quarterly earnings results on Tuesday, July 23rd. The company reported $5.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.97 by $0.53. HCA Healthcare had a return on equity of 553.13% and a net margin of 8.40%. The firm had revenue of $17.49 billion during the quarter, compared to the consensus estimate of $17.05 billion. During the same quarter in the previous year, the business earned $4.29 earnings per share. The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. As a group, sell-side analysts expect that HCA Healthcare, Inc. will post 22.51 EPS for the current year.

Insiders Place Their Bets

In related news, EVP Michael S. Cuffe sold 8,358 shares of HCA Healthcare stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $385.42, for a total transaction of $3,221,340.36. Following the transaction, the executive vice president now owns 29,678 shares in the company, valued at approximately $11,438,494.76. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, EVP Michael S. Cuffe sold 8,358 shares of the firm’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $385.42, for a total transaction of $3,221,340.36. Following the sale, the executive vice president now directly owns 29,678 shares in the company, valued at approximately $11,438,494.76. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Kathryn A. Torres sold 1,857 shares of the stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $355.05, for a total transaction of $659,327.85. Following the completion of the sale, the senior vice president now directly owns 17,755 shares of the company’s stock, valued at $6,303,912.75. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 17,202 shares of company stock worth $6,407,273 over the last ninety days. 1.60% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

HCA has been the topic of a number of recent research reports. UBS Group lifted their target price on shares of HCA Healthcare from $405.00 to $438.00 and gave the company a “buy” rating in a report on Wednesday, August 14th. Truist Financial raised their price target on HCA Healthcare from $390.00 to $430.00 and gave the stock a “buy” rating in a report on Monday, August 19th. Morgan Stanley started coverage on HCA Healthcare in a research report on Tuesday, September 3rd. They set an “equal weight” rating and a $427.00 price objective for the company. Oppenheimer upped their price objective on shares of HCA Healthcare from $345.00 to $390.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. Finally, StockNews.com upgraded shares of HCA Healthcare from a “buy” rating to a “strong-buy” rating in a report on Monday, July 1st. Five equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and four have given a strong buy rating to the stock. According to data from MarketBeat, HCA Healthcare presently has an average rating of “Moderate Buy” and a consensus target price of $367.15.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.